Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0755
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Kinase Inhibitor Screening Identifies CDK4 as a Potential Therapeutic Target for Melanoma

International Journal of Oncology
Cancer ResearchOncology
2015English

CDK4 Expression in Chordoma: A Potential Therapeutic Target Running Title: CDK4 Expression in Chordoma

Journal of Orthopaedic Research
OrthopedicsSports Medicine
2017English

CDK4 as a Phytochemical Based Anticancer Drug Target

2019English

A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma

Clinical Cancer Research
Cancer ResearchOncology
2018English

A Novel Tankyrase Inhibitor, MSC2504877, Enhances the Effects of Clinical CDK4/6 Inhibitors

Scientific Reports
Multidisciplinary
2019English

P16 Methylation Increases the Sensitivity of Cancer Cells to the CDK4/6 Inhibitor Palbociclib

PLoS ONE
Multidisciplinary
2019English

P16 Methylation Increases the Sensitivity of Cancer Cells to the CDK4/6 Inhibitor Palbociclib

2019English

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Cdk4/6-Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status

Clinical Cancer Research
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy